These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17950830)

  • 1. Design criteria for the ideal drug-eluting stent.
    Ako J; Bonneau HN; Honda Y; Fitzgerald PJ
    Am J Cardiol; 2007 Oct; 100(8B):3M-9M. PubMed ID: 17950830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical appraisal of the safety and efficacy of drug-eluting stents.
    Maluenda G; Lemesle G; Waksman R
    Clin Pharmacol Ther; 2009 May; 85(5):474-80. PubMed ID: 19279567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of current devices and a look at new technology: drug-eluting stents.
    Nakazawa G; Finn AV; Kolodgie FD; Virmani R
    Expert Rev Med Devices; 2009 Jan; 6(1):33-42. PubMed ID: 19105778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular remodeling after coronary stent implantation.
    Vorpahl M; Virmani R; Ladich E; Finn AV
    Minerva Cardioangiol; 2009 Oct; 57(5):621-8. PubMed ID: 19838152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary stents: looking forward.
    Garg S; Serruys PW
    J Am Coll Cardiol; 2010 Aug; 56(10 Suppl):S43-78. PubMed ID: 20797503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stent safety.
    Slottow TL; Waksman R
    Am J Cardiol; 2007 Oct; 100(8B):10M-17M. PubMed ID: 17950827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stents for coronary artery disease: a review.
    Martin DM; Boyle FJ
    Med Eng Phys; 2011 Mar; 33(2):148-63. PubMed ID: 21075668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xience V everolimus-eluting coronary stent.
    Kukreja N; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent.
    Kandzari DE; Leon MB
    J Interv Cardiol; 2006 Oct; 19(5):405-13. PubMed ID: 17020565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of drug-eluting stents.
    Windecker S; Jüni P
    Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):316-28. PubMed ID: 18414453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expectation for new-generation drug eluting stents].
    Saito S
    Nihon Rinsho; 2011 Feb; 69(2):237-9. PubMed ID: 21387669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing.
    Pendyala L; Jabara R; Robinson K; Chronos N
    J Interv Cardiol; 2009 Feb; 22(1):37-48. PubMed ID: 19281521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients.
    Gershlick A; Kandzari DE; Leon MB; Wijns W; Meredith IT; Fajadet J; Popma JJ; Fitzgerald PJ; Kuntz RE;
    Am J Cardiol; 2007 Oct; 100(8B):45M-55M. PubMed ID: 17950832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bifurcation stenting: current strategies and new devices.
    Latib A; Colombo A; Sangiorgi GM
    Heart; 2009 Mar; 95(6):495-504. PubMed ID: 18812408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents for coronary bifurcations: bench testing of provisional side-branch strategies.
    Ormiston JA; Webster MW; El Jack S; Ruygrok PN; Stewart JT; Scott D; Currie E; Panther MJ; Shaw B; O'Shaughnessy B
    Catheter Cardiovasc Interv; 2006 Jan; 67(1):49-55. PubMed ID: 16003787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.